Vancomycin Monitoring in Children Using Bayesian Estimation
暂无分享,去创建一个
E. Capparelli | J. Le | J. Bradley | G. Romanowski | Austin Nguyen | W. Murray | B. Ngu | T. Vo | L. Nguyen | A. Nguyen
[1] Roger W. Jelliffe,et al. Are Vancomycin Trough Concentrations Adequate for Optimal Dosing? , 2013, Antimicrobial Agents and Chemotherapy.
[2] B. Guglielmo,et al. Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.
[3] A. Raszynski,et al. Acute Kidney Injury During Vancomycin Therapy in Critically Ill Children , 2013, Pharmacotherapy.
[4] E. Capparelli,et al. Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure , 2013, The Pediatric infectious disease journal.
[5] J. Cies,et al. Nephrotoxicity in Patients with Vancomycin Trough Concentrations of 15–20 μg/ml in a Pediatric Intensive Care Unit , 2013, Pharmacotherapy.
[6] B. Moffett,et al. Analysis of Vancomycin Therapeutic Drug Monitoring Trends at Pediatric Hospitals , 2013, The Pediatric infectious disease journal.
[7] J. Carapetis,et al. Trough Concentrations of Vancomycin: Adult Therapeutic Targets Are Not Appropriate for Children , 2012, The Pediatric infectious disease journal.
[8] Yuhki Sato,et al. Is Peak Concentration Needed in Therapeutic Drug Monitoring of Vancomycin? A Pharmacokinetic-Pharmacodynamic Analysis in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia , 2012, Chemotherapy.
[9] Jana Shaw,et al. Inappropriate vancomycin therapeutic drug monitoring in hospitalized pediatric patients increases pediatric trauma and hospital costs. , 2012, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.
[10] B. Meibohm,et al. Creatinine‐Based Vancomycin Dosing Regimens in Neonates: There Is More to Consider Than the Variation in Drug Assay , 2012, Pharmacotherapy.
[11] Lisa Tang,et al. Evaluation of Vancomycin Dosing Regimens in Preterm and Term Neonates Using Monte Carlo Simulations , 2012, Pharmacotherapy.
[12] D. Paterson,et al. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] R. Kullar,et al. Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort , 2012, Pharmacotherapy.
[14] G. Drusano,et al. Vancomycin: we can't get there from here. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] M. Jahng,et al. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. , 2011, The Journal of pediatrics.
[16] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] M. H. Ensom,et al. Limited Sampling Strategies for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Islet Transplant Recipients , 2010, The Annals of pharmacotherapy.
[18] D. Levine,et al. Therapeutic Monitoring of Vancomycin in Adults , 2009, Pharmacotherapy.
[19] L. Benet,et al. Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is Inadequate , 2009, The Pediatric infectious disease journal.
[20] A. Wong-Beringer,et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. , 2006, Archives of internal medicine.
[21] Mary H. H. Ensom,et al. Beyond Cyclosporine: A Systematic Review of Limited Sampling Strategies for Other Immunosuppressants , 2006, Therapeutic drug monitoring.
[22] D. Greenblatt,et al. Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques , 2002, Journal of clinical pharmacology.
[23] M. Barclay,et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve. , 1995, Australian and New Zealand journal of medicine.
[24] M. Wysocki,et al. Why monitor peak vancomycin concentrations? , 1995, The Lancet.
[25] S. Boike,et al. Monitoring Vancomycin Therapy , 1986, Drug intelligence & clinical pharmacy.
[26] R. Jelliffe,et al. Title: Are vancomycin troughs adequate for optimal dosing? , 2013 .
[27] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[29] P. Marquet,et al. Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus , 2009, Clinical pharmacokinetics.
[30] Jerome J. Schentag,et al. Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.